CN111793140A - 一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途 - Google Patents
一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途 Download PDFInfo
- Publication number
- CN111793140A CN111793140A CN202010603645.XA CN202010603645A CN111793140A CN 111793140 A CN111793140 A CN 111793140A CN 202010603645 A CN202010603645 A CN 202010603645A CN 111793140 A CN111793140 A CN 111793140A
- Authority
- CN
- China
- Prior art keywords
- oligosaccharide
- black fungus
- auricularia auricula
- oxidative damage
- protecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000233866 Fungi Species 0.000 title claims abstract description 65
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 59
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 59
- 230000004792 oxidative damage Effects 0.000 title claims abstract description 27
- 210000005229 liver cell Anatomy 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 235000000023 Auricularia auricula Nutrition 0.000 claims abstract description 61
- 241001149430 Auricularia auricula-judae Species 0.000 claims abstract description 61
- 108090000790 Enzymes Proteins 0.000 claims abstract description 18
- 102000004190 Enzymes Human genes 0.000 claims abstract description 18
- 238000001914 filtration Methods 0.000 claims abstract description 17
- 238000000605 extraction Methods 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 238000000265 homogenisation Methods 0.000 claims abstract description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 33
- 150000004676 glycans Chemical class 0.000 claims description 30
- 229920001282 polysaccharide Polymers 0.000 claims description 28
- 239000005017 polysaccharide Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 16
- 239000008367 deionised water Substances 0.000 claims description 15
- 229910021641 deionized water Inorganic materials 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 14
- 108010059820 Polygalacturonase Proteins 0.000 claims description 11
- 235000019441 ethanol Nutrition 0.000 claims description 11
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 11
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 10
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 10
- 238000001125 extrusion Methods 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-Butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000003760 magnetic stirring Methods 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 abstract description 6
- 238000000926 separation method Methods 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 239000000084 colloidal system Substances 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000012528 membrane Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002033 PVDF binder Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000221377 Auricularia Species 0.000 description 6
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000413 hydrolysate Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000874 microwave-assisted extraction Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01015—Polygalacturonase (3.2.1.15)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Sustainable Development (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途,属于食用菌有效成分制备领域。其黑木耳寡糖是由黑木耳干燥子实体经快速均质结合酶法提取,挤压过滤及除蛋白,离子交换层析获得。该制备方法缩短了提取时间、减少了试剂用量、节约了能源、提高了溶解性,并且采用的挤压过滤方法适用于胶质含量较高的粘稠溶液的分离;同时该黑木耳寡糖具有保护肝细胞氧化损伤的功能,可用于制备保肝、护肝辅助药品、保健食品,为黑木耳深加工产品开发提供基础数据,具有重要的经济和市场价值。
Description
技术领域
本发明涉及一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途,属于天然产物领域。
背景技术
肝脏是人体腹腔内最大的代谢器官,起着调节免疫耐受、合成蛋白、维护机体内环境平衡的作用。我国每年死于肝脏疾病的患者超过40万的患者,而肝损伤是多种肝病共有的生理状态。熬夜、劳累、醉酒、病毒、药物、遗传等均是引发肝损伤的原因,但是各种诱因引发得肝损伤均会伴随氧化应激、脂质过氧化物堆积等过氧化状态。黑木耳是我国主要的食用菌品种,年生产量及消费量均在食用菌中位居前列。黑木耳多糖是黑木耳重要的活性成分,具有降血糖、降血脂、增强免疫、抗凝血等多种生物活性,也发现其具有保护卡介苗引起的免疫性肝损伤,但是并不清楚多糖结构特征及作用通路。
此外,黑木耳多糖的提取制备方法以热水提取最为简单也最常使用,但存在提取时间长、所用溶剂量大、高温易破坏多糖结构等缺点(魏红.黑木耳多糖的提取工艺[J].食品研究与开发,2010,05:117~120.)。而且,黑木耳多糖大部分为胶质成分,水提物粘稠度高亦被称为“非牛顿流体”,因此在提取过程中也常加入酸、碱及生物酶辅助提取,以提高黑木耳流动性。但是,酸、碱会破坏多糖结构,生物酶的加入也使提取条件受到了限制,只能在酶的最适温度、pH范围内进行,而且后续分离纯化时需要将其灭活、去除,酶制剂费用较高(李啸.响应面法优化酶法提取黑木耳活性多糖的条件[J].安徽农业科学,2010,33:475~478.);超声波辅助提取噪音较大(徐秀卉.超声波法提取黑木耳多糖的工艺[J].药学与临床研究,2011,2(19):189~190.);而微波辅助提取受设备限制,提取量较小(朱磊.响应面法优化微波辅助提取黑木耳多糖工艺研究[J].中国食品学报,2009,02:58~65.)。上述现有技术均不能满足该类产品产业化开发及生产的大量需求。
发明内容
本发明是针对现有研究及技术的不足,旨在提供一种保护肝细胞氧化损伤的黑木耳寡糖及其制备方法和用途。
本发明所述的一种保护肝细胞氧化损伤的黑木耳寡糖,该黑木耳寡糖是为β型吡喃糖,由岩藻糖、阿拉伯糖、半乳糖、葡萄糖、木糖、甘露糖组成,分子量范围6.882×103~22.684×103Da。
所述的一种保护肝细胞氧化损伤的黑木耳寡糖的制备方法,是该黑木耳寡糖由黑木耳干燥子实体经快速均质结合酶法提取,挤压过滤及除蛋白,离子交换层析获得。
上述制备方法具体步骤如下:
a、对黑木耳干燥子实体进行粉碎,过40目筛,形成黑木耳干燥子实体粉末,将黑木耳干燥子实体粉末装入均质机中,按料液比1:30~1:100加入去离子水,均质5~20min,加10mg/mL果胶酶溶液,使果胶酶的质量为黑木耳干燥子实体粉末的0.4%,形成黑木耳酶提取液,对黑木耳酶提取液进行挤压过滤,制备成黑木耳过滤液,在80~100℃温度下将黑木耳过滤液浓缩至原有体积1/2~1/3后,冷却至室温,加3~4倍浓缩后黑木耳过滤液体积的无水乙醇,形成混合液1,在4℃温度下,将混合液1静置12h,以6000~10000r/min转速进行离心,离心时间5~10min,离心后挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体粗多糖;
b、加入纯净水,将黑木耳子实体粗多糖配制成5mg/mL溶液,加入氯仿正丁醇混合溶液,磁力搅拌,离心分层,提取上层溶液,重复加入氯仿正丁醇混合溶液1次,离心,取上清液进行减压浓缩至原体积1/2~1/3,加入浓缩后体积3~4倍的无水乙醇,4℃温度下静置12h,以6000~10000r/min转速进行离心,离心5~10min,挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体多糖;
c、黑木耳子实体多糖加去离子水溶解,定容,上样DEAE52纤维素柱层析,用去离子水洗脱,流速5mL/3min,每管收集5mL,苯酚硫酸法测定各管糖含量,根据各管糖含量收集洗脱峰,获得黑木耳寡糖。
在一种保护肝细胞氧化损伤的黑木耳寡糖的制备方法中,所述的挤压过滤采用单螺杆挤压机,单螺杆挤压机的模孔直径为8~16mm、挤压机套筒温度为60~100℃、螺杆转速为160~260r/min。
上述的一种保护肝细胞氧化损伤的黑木耳寡糖在制备保健食品、药品中的用途。
一种可用于肝细胞氧化损伤的保健食品、药品组合物,所述保健食品、药品组合物中含有权利要求1~3所述的黑木耳寡糖成分。
上述的一种保护肝细胞氧化损伤的黑木耳寡糖的保健食品、药品组合物中,所述保健食品、药品组合物的剂型可以为片剂、颗粒剂、胶囊剂或溶液剂。
本发明积极效果在于:首次从黑木耳子实体中获得了一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途在制备保健食品、药品中的用途;并在该黑木耳寡糖制备过程中采用了黑木耳干燥子实体经快速均质结合酶法提取,挤压分离及除蛋白、离子层析的提取分离方法,缩短了提取时间、减少了试剂用量、节约了能源、提高了溶解性,并且采用的挤压过滤方法适用于胶质含量较高的粘稠溶液的分离;同时公开了该黑木耳寡糖可通过调控PI3K-akt信号通路保护肝细胞氧化损伤的功能活性,可用于制备保肝、护肝辅助药品、保健食品,为黑木耳深加工产品开发提供基础数据,具有重要的经济和市场价值。
附图说明
下面结合附图说明和具体实施方式对本发明作进一步说明:
图1为本发明黑木耳寡糖DEAE52洗脱曲线;
图2为本发明黑木耳寡糖高效凝胶渗透色谱洗脱曲线;
图3为本发明黑木耳寡糖单糖组成分析;
图4为本发明黑木耳寡糖的红外光谱;
图5为本发明黑木耳寡糖对氧化损伤HepG2细胞保护作用;
图6为本发明黑木耳寡糖对氧化损伤HepG2细胞形态影响;
图7为本发明黑木耳寡糖对HepG2细胞超氧化物歧化酶活性影响;
图8为本发明黑木耳寡糖对HepG2细胞过氧化氢酶活性影响;
图9为本发明黑木耳寡糖对HepG2细胞谷胱甘肽过氧化物酶活性影响;
图10为本发明黑木耳寡糖对HepG2细胞凋亡相关蛋白表达的影响。
具体实施方式
下面将结合具体实施方式进一步说明本发明,但本发明要求保护的范围并不局限于下列实施方式。
实施例1:
1、对黑木耳干燥子实体进行粉碎,过40目筛,形成黑木耳干燥子实体粉末,将黑木耳干燥子实体粉末装入均质机中,按料液比1:80加入去离子水,均质10min,加10mg/mL果胶酶溶液,使其酶的质量为黑木耳干燥子实体粉末的0.4%,50℃水浴锅中恒温加热反应1小时,再将烧杯放置于90℃水浴中1小时,灭活果胶酶活性,进行挤压过滤。挤压过滤采用单螺旋杆挤压机,挤压机模孔的直径为16mm、挤压机套筒的温度60℃、螺杆转速240r/min。90℃下黑木耳过滤液将浓缩至原有体积1/3,冷却至室温,加3倍体积无水乙醇,4℃静置12h,10000r/min,离心5min,挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体粗多糖。
2、黑木耳子实体粗多糖配制成5mg/mL溶液,加入氯仿正丁醇混合溶液,磁力搅拌,离心分层,提取上层溶液,重复加入氯仿正丁醇混合溶液1次,离心,取上清液进行减压浓缩至原体积1/2,加入4倍无水乙醇,4℃静置12h,10000r/min,离心5min,挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体多糖。
3、黑木耳子实体多糖加去离子水溶解,定容,上样DEAE52纤维素柱层析(4.0×30cm),去离子水洗脱,流速5mL/3min,每管收集5mL。苯酚硫酸法测定各管糖含量,根据各管糖含量收集洗脱峰,如图1所示,获得黑木耳寡糖,继续将黑木耳寡糖进行凝胶渗透色谱分析(TSK-gelG-3000PWXL色谱柱(7.8×300mm)),色谱条件:色谱柱:DionexTMCarboPacTMPA20。流动相:A相:ddH2O;B相:200mMNaOH;C相:200mMNaOH/500mMNaAC。流速:0.5mL/min。分子量以lgMw=7.831-0.228t+计算,获得平均分子量为16.190kDa的黑木耳寡糖,如图2所示。红外光谱检测黑木耳寡糖为β型吡喃糖,取2mg黑木耳寡糖通过含有1MHCl的甲醇水解,水解产物通过2MTFA水解后,水解产物通过1-苯基-3-甲基-5-吡唑啉酮(PMP)衍生化后,产物经CompassC18column(250×4.6mm)色谱柱分离,HPLC分析,UV245nm检测洗脱产物,结果如图3所示。结果表明,黑木耳寡糖主要由葡萄糖、半乳糖、甘露糖组成,并含有少量的岩藻糖、阿拉伯糖、木糖。
实施例2:
1、对黑木耳干燥子实体进行粉碎,过40目筛,形成黑木耳干燥子实体粉末,将黑木耳干燥子实体粉末装入均质机中,按料液比1:100加入去离子水,均质5min,加10mg/mL果胶酶溶液,使其酶质量为黑木耳干燥子实体粉末的0.4%,50℃水浴锅中恒温加热反应1小时,再将烧杯放置于100℃水浴中1小时,灭活果胶酶活性,进行挤压过滤。挤压过滤采用单螺旋杆挤压机,挤压机模孔的直径8mm、挤压机套筒的温度80℃、螺杆转速160r/min。100℃下黑木耳过滤液将浓缩至原有体积1/2,冷却至室温,加3倍体积无水乙醇,4℃静置12h,6000r/min,离心10min,挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体粗多糖。
2、黑木耳子实体粗多糖配制成5mg/mL溶液,加入氯仿正丁醇混合溶液(体积比4:1),磁力搅拌,离心分层,提取上层溶液,重复加入氯仿正丁醇混合溶液(体积比4:1)1次,离心,取上清液进行减压浓缩至原体积1/2,加入3倍无水乙醇,4℃静置12h,6000r/min,离心10min,挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体多糖。
3、黑木耳子实体多糖加去离子水溶解,定容,上样DEAE52纤维素柱层析(4.0×30cm),去离子水洗脱,流速5mL/3min,每管收集5mL。苯酚硫酸法测定各管糖含量,根据各管糖含量收集洗脱峰,如图1所示,获得黑木耳寡糖,继续将黑木耳寡糖进行凝胶渗透色谱分析(TSK-gelG-3000PWXL色谱柱(7.8×300mm)),色谱条件:色谱柱:DionexTMCarboPacTMPA20。流动相:A相:ddH2O;B相:200mMNaOH;C相:200mMNaOH/500mMNaAC。流速:0.5mL/min。分子量以lgMw=7.831-0.228t+计算,获得平均分子量为22.684×103Da的黑木耳寡糖,如图2所示。红外光谱检测黑木耳寡糖为β型吡喃糖,取2mg黑木耳寡糖通过含有1MHCl的甲醇水解,水解产物通过2MTFA水解后,水解产物通过1-苯基-3-甲基-5-吡唑啉酮(PMP)衍生化后,产物经CompassC18column(250×4.6mm)色谱柱分离,HPLC分析,UV245nm检测洗脱产物,结果如图3所示。结果表明,黑木耳寡糖主要由葡萄糖、半乳糖、甘露糖组成,并含有少量的岩藻糖、阿拉伯糖、木糖。
实施例3:
1、对黑木耳干燥子实体进行粉碎,过40目筛,形成黑木耳干燥子实体粉末,将黑木耳干燥子实体粉末装入均质机中,按料液比1:30加入去离子水,均质20min,加10mg/mL果胶酶溶液,使其酶质量为黑木耳干燥子实体粉末的0.4%,50℃水浴锅中恒温加热反应1小时,再将烧杯放置于80℃水浴中1小时,灭活果胶酶活性,进行挤压过滤。挤压过滤采用单螺旋杆挤压机,挤压机模孔直径16mm、挤压机套筒温度100℃、螺杆转速260r/min。80℃下黑木耳过滤液将浓缩至原有体积1/3,冷却至室温,加4倍体积无水乙醇,4℃静置12h,8000r/min,离心8min,挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体粗多糖。
2、黑木耳子实体粗多糖配制成5mg/mL溶液,加入氯仿正丁醇混合溶液(体积比4:1),磁力搅拌,离心分层,提取上层溶液,重复加入氯仿正丁醇混合溶液(体积比4:1)1次,离心,取上清液进行减压浓缩至原体积1/3,加入4倍无水乙醇,4℃静置12h,8000r/min,离心8min,挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体多糖。
3、黑木耳子实体多糖加去离子水溶解,定容,上样DEAE52纤维素柱层析(4.0×30cm),去离子水洗脱,流速5mL/3min,每管收集5mL。苯酚硫酸法测定各管糖含量,根据各管糖含量收集洗脱峰,如图1所示,获得黑木耳寡糖,继续将黑木耳寡糖进行凝胶渗透色谱分析(TSK-gelG-3000PWXL色谱柱(7.8×300mm)),色谱条件:色谱柱:DionexTMCarboPacTMPA20。流动相:A相:ddH2O;B相:200mMNaOH;C相:200mMNaOH/500mMNaAC。流速:0.5mL/min。分子量以lgMw=7.831-0.228t+计算,获得平均分子量6.882×103的黑木耳寡糖,如图2所示。红外光谱检测AHP-0为β型吡喃糖,取2mg黑木耳寡糖通过含有1MHCl的甲醇水解,水解产物通过2MTFA水解后,水解产物通过1-苯基-3-甲基-5-吡唑啉酮(PMP)衍生化后,产物经CompassC18column(250×4.6mm)色谱柱分离,HPLC分析,UV245nm检测洗脱产物,结果如图3所示。结果表明,黑木耳寡糖主要由葡萄糖、半乳糖、甘露糖组成,并含有少量的岩藻糖、阿拉伯糖、木糖。
通过以下试验证明本发明一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途:
试验例1:
将处于对数生长期的细胞消化为细胞悬液,调整细胞浓度为4×104个/mL,铺板96孔板每孔100μL,5%浓度CO2培养箱培养24h。吸去培养基,按实验分组分别加入相应培养液100μL。实验分为6组,空白对照组加入无血清培养基;实验组加入分别含125、250、500和1000μg/mL的黑木耳寡糖及0.7mmol/LH2O2的完全培养液;模型对照组加入含0.7mmol/LH2O2的完全培养液,每组设6个重复。5%浓度CO2培养箱培养48h,吸弃含药培养液,加入100μL含有10%CCK-8的新鲜无血清培养基,孵育1h。酶标仪490nm检测各孔吸光度,并计算各组IC50。
试验例2:
选取对数生长期的HepG2细胞,调整细胞浓度为1×106/mL,接种于6孔板中,培养箱培养24h。分别以浓度125、250、500和1000μg/mL的黑木耳寡糖与0.7mmol/LH2O2同时处理HepG2细胞24h。弃去培养基,DPBS洗涤3遍。加70%冰乙醇,4℃固定15min。DPBS洗3遍,1%结晶紫溶液室温染色10min后DPBS再次洗涤3遍。适宜放大倍数镜检并拍照。
试验例3:
将对数生长期的HepG2细胞以2×106个/mL接种于6孔板,培养24h后,处理条件同试验例1。收集培养液并重悬细胞,根据制造商提供的实验方案,使用市售试剂盒(T-SOD、CAT、GSH-Px检测试剂盒),分别测量细胞上清液中的抗氧化酶水平。实验结果使用酶联免疫酶标仪在不同吸光度下测量数值表示。每组数据设置3个重复对照孔。
试验例4:
将处于对数生长期的HepG2细胞传代至10cm无菌培养皿,贴壁培养24h。胰酶消化,离心收集细胞。实验分6组,分别为实验对照组,损伤模型组(0.7mmol/L过氧化氢)和不同浓度黑木耳寡糖(125、250、500和1000μg/mL)给药实验组。按组别分别加入对应培养液培养24h后,弃去培养基,预冷DPBS洗涤2次。胰酶消化细胞,加1mL含PMSF的裂解液,冰上裂解30min,期间不时振动离心管,以便裂解完全。12000rpm/min,4℃离心10min,上清用于测定蛋白含量。采用BCA试剂盒测定蛋白含量,将样品与Lodaing Buffer混合,95℃加热5min以变性蛋白。将变性蛋白分装后-20℃保存。根据不同蛋白分子量大小,选择不同密度预制胶,电泳液使用超纯水现用现制。取上述变性蛋白样品,进行SDS-PAGE电泳。电泳条件为恒压110V、75min,直至溴酚蓝指示染液距离凝胶低端1cm左右停止电泳,转膜。转膜后,立即将PVDF膜放入TBST缓冲液中漂洗1~2min,洗去残留液体。将PVDF膜置于5%BSA中,摇床速度10rpm/min,4℃条件下封闭60min。将封闭后的PVDF膜完全浸泡在一抗稀释液中(按1:1000比例稀释)中。摇床转速2rpm/min,4℃避光孵育过夜。镊子取出PVDF膜后TBST缓冲液漂洗4次,5min/次。洗涤后将PVDF膜置于二抗辣根过氧化物酶(HRP)中,4℃避光孵育60min。TBST漂洗4次,每次5min,摇床转速4rpm/min。二抗孵育完成后,取出PVDF膜,TBST溶液洗涤3次,5min/次。根据化学发光试剂盒说明书,将A、B液按体积比1:1避光混合。PVDF膜置于ChemiDocXRS(Bio-Rad)仪器内,将混合后的发光试剂均匀的滴加于PVDF膜上,室温避光反应2min,选择信号累计模式,凝胶成像仪自动曝光,保存图片。
上述抗氧化酶酶活性检测及活性氧生成实验结果如图5~图10所示,当黑木耳寡糖的浓度为0.25~1.0mg/mL时,通过调控PI3k-akt细胞信号通路抑制氧化损伤肝细胞的死亡,并提高氧化损伤肝细胞抗氧化酶活性,对肝细胞的氧化损伤具有保护作用。
本发明实施方式说明到此结束。
Claims (7)
1.一种保护肝细胞氧化损伤的黑木耳寡糖,其特征在于,该黑木耳寡糖是为β型吡喃糖,由岩藻糖、阿拉伯糖、半乳糖、葡萄糖、木糖、甘露糖组成,分子量范围6.882×103~22.684×103Da。
2.根据权利要求1所述的一种保护肝细胞氧化损伤的黑木耳寡糖的制备方法,其特征在于:该黑木耳寡糖由黑木耳干燥子实体经快速均质结合酶法提取,挤压过滤及除蛋白,离子交换层析获得。
3.根据权利要求2所述的一种保护肝细胞氧化损伤的黑木耳寡糖的制备方法,其特征在于:上述制备方法具体步骤如下:
a、对黑木耳干燥子实体进行粉碎,过40目筛,形成黑木耳干燥子实体粉末,将黑木耳干燥子实体粉末装入均质机中,按料液比1:30~1:100加入去离子水,均质5~20min,加10mg/mL果胶酶溶液,使果胶酶的质量为黑木耳干燥子实体粉末的0.4%,形成黑木耳酶提取液,50℃水浴锅中恒温加热反应1小时,再将烧杯放置于90℃水浴中1小时,灭活果胶酶活性,对黑木耳酶提取液进行挤压过滤,制备成黑木耳过滤液,在80~100℃温度下将黑木耳过滤液浓缩至原有体积1/2~1/3后,冷却至室温,加3~4倍浓缩后黑木耳过滤液体积的无水乙醇,形成混合液1,在4℃温度下,将混合液1静置12h,以6000~10000r/min转速进行离心,离心时间5~10min,离心后挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体粗多糖;
b、加入纯净水,将黑木耳子实体粗多糖配制成5mg/mL溶液,加入氯仿正丁醇混合溶液,磁力搅拌,离心分层,提取上层溶液,重复加入氯仿正丁醇混合溶液1次,离心,取上清液进行减压浓缩至原体积1/2~1/3,加入浓缩后体积3~4倍的无水乙醇,4℃温度下静置12h,以6000~10000r/min转速进行离心,离心5~10min,挥发残余乙醇,冷冻干燥,干燥粉末即为黑木耳子实体多糖;
c、黑木耳子实体多糖加去离子水溶解,定容,上样DEAE 52纤维素柱层析,用去离子水洗脱,流速5mL/3min,每管收集5mL,苯酚硫酸法测定各管糖含量,根据各管糖含量收集洗脱峰,获得黑木耳寡糖。
4.根据权利要求2和3所述的一种保护肝细胞氧化损伤的黑木耳寡糖的制备方法,其特征在于:所述的挤压过滤采用单螺杆挤压机,单螺杆挤压机的模孔直径为8~16mm、挤压机套筒温度为60~100℃、螺杆转速为160~260r/min。
5.根据权利要求1~3所述的一种保护肝细胞氧化损伤的黑木耳寡糖在制备保健食品、药品中的用途。
6.一种可用于肝细胞氧化损伤的保健食品、药品组合物,其特征在于:所述保健食品、药品组合物中含有权利要求1~3所述的黑木耳寡糖成分。
7.根据权利要求6所述的一种保护肝细胞氧化损伤的黑木耳寡糖的保健食品、药品组合物,其特征在于:所述保健食品、药品组合物的剂型可以为片剂、颗粒剂、胶囊剂或溶液剂。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010603645.XA CN111793140A (zh) | 2020-06-29 | 2020-06-29 | 一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途 |
NL2027683A NL2027683B1 (en) | 2020-06-29 | 2021-03-02 | Auricularia heimuer Oligosaccharide for Protecting Hepatocytes from Oxidative Damage, Preparation Method Thereof and Use Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010603645.XA CN111793140A (zh) | 2020-06-29 | 2020-06-29 | 一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111793140A true CN111793140A (zh) | 2020-10-20 |
Family
ID=72804672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010603645.XA Pending CN111793140A (zh) | 2020-06-29 | 2020-06-29 | 一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111793140A (zh) |
NL (1) | NL2027683B1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114409820A (zh) * | 2022-01-27 | 2022-04-29 | 吉林农业大学 | 一种玉木耳含铁甘露聚糖的制备方法及其产品和应用 |
CN114524885A (zh) * | 2022-02-18 | 2022-05-24 | 吉林农业大学 | 一种黑木耳多糖及其应用 |
CN114588175A (zh) * | 2022-04-22 | 2022-06-07 | 吉林农业大学 | 黑木耳膳食纤维在酒精性肝损伤中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102585032A (zh) * | 2012-03-09 | 2012-07-18 | 武汉大学 | 一种从黑木耳中提取的水溶性多糖及其制备方法 |
CN103772522A (zh) * | 2014-01-13 | 2014-05-07 | 东北林业大学 | 高分子乳化剪切提取黑木耳多糖的方法 |
CN110522028A (zh) * | 2019-09-29 | 2019-12-03 | 承德润雨科技有限公司 | 一种护肝抗疲劳的组合物及其应用 |
CN111217926A (zh) * | 2018-11-23 | 2020-06-02 | 南京泽朗医药科技有限公司 | 一种高速剪切乳化提取黑木耳多糖的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102021104013A1 (de) * | 2021-02-19 | 2022-08-25 | Andrea Lexut | Gelbildende Extrakte aus den Pilzen der Gattung Ohrlappenpilze (Auricularia) sowie Verfahren zu deren Herstellung |
-
2020
- 2020-06-29 CN CN202010603645.XA patent/CN111793140A/zh active Pending
-
2021
- 2021-03-02 NL NL2027683A patent/NL2027683B1/en active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102585032A (zh) * | 2012-03-09 | 2012-07-18 | 武汉大学 | 一种从黑木耳中提取的水溶性多糖及其制备方法 |
CN103772522A (zh) * | 2014-01-13 | 2014-05-07 | 东北林业大学 | 高分子乳化剪切提取黑木耳多糖的方法 |
CN111217926A (zh) * | 2018-11-23 | 2020-06-02 | 南京泽朗医药科技有限公司 | 一种高速剪切乳化提取黑木耳多糖的方法 |
CN110522028A (zh) * | 2019-09-29 | 2019-12-03 | 承德润雨科技有限公司 | 一种护肝抗疲劳的组合物及其应用 |
Non-Patent Citations (3)
Title |
---|
H.-D BELITZ等编著,石阶平等译: "《食品化学》", 28 February 2008, 中国农业大学出版社 * |
李乃胜等: "《中国海洋水产品现代加工技术与质量安全》", 31 May 2010, 海洋出版社 * |
杨晖等: ""不同贮藏时间对食用菌多糖含量及其抗氧化活性的影响"", 《浙江大学学报(农业与生命科学版)》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114409820A (zh) * | 2022-01-27 | 2022-04-29 | 吉林农业大学 | 一种玉木耳含铁甘露聚糖的制备方法及其产品和应用 |
CN114409820B (zh) * | 2022-01-27 | 2022-10-28 | 吉林农业大学 | 一种玉木耳含铁甘露聚糖的制备方法及其产品和应用 |
CN114524885A (zh) * | 2022-02-18 | 2022-05-24 | 吉林农业大学 | 一种黑木耳多糖及其应用 |
CN114588175A (zh) * | 2022-04-22 | 2022-06-07 | 吉林农业大学 | 黑木耳膳食纤维在酒精性肝损伤中的应用 |
Also Published As
Publication number | Publication date |
---|---|
NL2027683A (en) | 2022-02-17 |
NL2027683B1 (en) | 2023-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111793140A (zh) | 一种保护肝细胞氧化损伤的黑木耳寡糖及制备方法和用途 | |
WO2019205662A1 (zh) | 一种蛹虫草培养基多糖及其分离纯化方法和用途 | |
CN111704678B (zh) | 一种平菇半乳甘露葡聚糖及其制备方法和用途 | |
WO2022218174A1 (zh) | 一种面膜液的制备方法及面膜产品和应用 | |
WO2022218173A1 (zh) | 一种面膜液、其制备方法及应用 | |
Foster et al. | Application of ethylenediaminetetra-acetic acid in the isolation of crustacean chitin | |
CN117247430B (zh) | 一种玉米抗氧化肽及其制备方法与应用 | |
CN115960167A (zh) | 一种玉米抗粘附肽及其制备方法和应用 | |
CN111671069A (zh) | 一种从破壁松花粉中提取松花粉壁的方法 | |
CN110551234A (zh) | 一种葛根多糖的制备方法及葛根多糖作为促生长剂的应用 | |
JP5705264B2 (ja) | 網膜細胞保護用の銀耳多糖類及びその製造方法 | |
CN112807322A (zh) | 低聚甘露糖醛酸盐在制备延缓皮肤衰老和免疫抗炎的药物和功能性食品中的应用 | |
CN114796310B (zh) | 一种含有atcc9080菌种发酵产物的药物组合物、其制备方法及应用 | |
CN109988251B (zh) | 一种具有抗氧化活性的金针菇酸性多糖的制备方法 | |
CN112336667A (zh) | 一种布渣叶提取物及其制备方法和应用 | |
CN111690705A (zh) | 一种柞蚕蛹虫草生物活性肽的制备方法 | |
CN107177513B (zh) | 团青霉t3-1及其发酵化合物、提取纯化方法和在抗过敏中的应用 | |
CN117653566B (zh) | 包含药用层孔菌的提取组合物及其应用 | |
CN111345418A (zh) | 一种药食同源酵素饮料及其制备方法 | |
CN111057115A (zh) | 一种从贵妃蚌中提取的抗血栓类肝素及其制备方法和应用 | |
CN111471733B (zh) | 一种大星鲨鱼皮多肽干粉的制备方法和应用 | |
CN116496426B (zh) | 一种螺旋藻多糖胶体及其制备方法和应用 | |
CN112370397B (zh) | 布渣叶提取物及其制剂在护肤品中的应用、护肤品 | |
CN115819639B (zh) | 一种小分子量铁皮石斛多糖的制备方法及其用途 | |
CN113230287B (zh) | 灵芝和/或桦树茸在制备抗炎症因子产品、调控抗菌肽方面的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |